Clinical Trials Browser

Phase 2 × tildrakizumab × Clear all

NCT04112810 2025-10-21

Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease

Phase 2 Completed

51 enrolled 19 charts

Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms